Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 12/20 | 0.59 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.44 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.41 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.41 |
| ▸ | F10 | P00742 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.38 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.38 |
| ▸ | F9 | P00740 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL462839 | 0.84 | NOTUM (0.56) | NOTUMCYP19A1KCNJ1KEAP1RAB9A | |
| SCHEMBL18865501 | 0.82 | KCNJ1 (0.62) | NOTUMCYP19A1KCNJ1KEAP1RAB9A | |
| SCHEMBL6827358 | 0.82 | NOTUM (0.55) | NOTUMCYP19A1KCNJ1KEAP1RAB9A | |
| SCHEMBL10447781 | 0.80 | NOTUM (0.78) | NOTUMCYP19A1KEAP1 | |
| SCHEMBL15520031 | 0.78 | NOTUM (0.54) | NOTUMCYP19A1RAB9AMAPK9MAPK10 | |
| SCHEMBL31638362 | 0.78 | NOTUM (0.54) | NOTUMCYP19A1KCNJ1KEAP1 | |
| SCHEMBL6326873 | 0.78 | NOTUM (0.50) | NOTUMCYP19A1KCNJ1KEAP1MAPK9 | |
| SCHEMBL22391983 | 0.78 | HTT (0.55) | NOTUMCYP19A1 | |
| SCHEMBL470312 | 0.76 | KCNJ1 (0.69) | NOTUMKCNJ1RAB9A | |
| SCHEMBL17422567 | 0.76 | NOTUM (0.51) | NOTUMKEAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4559902-A2 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | Imago Biosciences Inc. (US) | 2025-05-28 | — | — | EP | disclosed |
| EP-3256218-B1 | A KDM1A INHIBITOR AND ITS USE IN THERAPY | IMAGO BIOSCIENCES INC (US) | 2024-12-11 | — | — | EP | disclosed |
| US-11773068-B2 | KDM1A inhibitors for the treatment of disease | IMAGO BIOSCIENCES, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-11773068-B2 | KDM1A inhibitors for the treatment of disease | IMAGO BIOSCIENCES, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-11773068-B2 | KDM1A inhibitors for the treatment of disease | IMAGO BIOSCIENCES, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-20230000835-A1 | LYSINE-SPECIFIC HISTONE DEMETHYLASE INHIBITORS FOR THE TREATMENT OF MYELOPROLIFERATIVE NEOPLASMS | IMAGO BIOSCIENCES, INC. | 2023-01-05 | — | — | US | disclosed |
| US-20220073477-A1 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | IMAGO BIOSCIENCES, INC. | 2022-03-10 | — | — | US | disclosed |
| US-11230534-B2 | KDM1A inhibitors for the treatment of disease | IMAGO BIOSCIENCES, INC. (US) | 2022-01-25 | — | — | US | disclosed |
| US-11230534-B2 | KDM1A inhibitors for the treatment of disease | IMAGO BIOSCIENCES, INC. (US) | 2022-01-25 | — | — | US | disclosed |
| CN-107427699-B | KDM1A inhibitors for the treatment of disease | 伊美格生物科学公司 | 2021-10-19 | — | — | CN | disclosed |
| EP-2614052-A1 | NOVEL PIPERAZINE ANALOGS AS BROAD-SPECTRUM INFLUENZA ANTIVIRALS | Bristol-Myers Squibb Company (US) | 2013-07-17 | — | — | EP | disclosed |
| CN-103201268-A | Novel piperazine analogs as broad-spectrum influenza antivirals | BRISTOL MYERS SQUIBB CO | 2013-07-10 | — | — | CN | disclosed |
| US-8362004-B2 | Piperazine analogs as broad-spectrum influenza antivirals | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-29 | — | — | US | disclosed |
| US-8362004-B2 | Piperazine analogs as broad-spectrum influenza antivirals | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-29 | — | — | US | disclosed |
| US-8362004-B2 | Piperazine analogs as broad-spectrum influenza antivirals | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-29 | — | — | US | disclosed |
| US-20120238539-A1 | NOVEL PIPERAZINE ANALOGS AS BROAD-SPECTRUM INFLUENZA ANTIVIRALS | BRISTOL-MYERS SQUIBB COMPANY | 2012-09-20 | — | — | US | disclosed |
| US-20120238539-A1 | NOVEL PIPERAZINE ANALOGS AS BROAD-SPECTRUM INFLUENZA ANTIVIRALS | BRISTOL-MYERS SQUIBB COMPANY | 2012-09-20 | — | — | US | disclosed |
| US-20120238539-A1 | NOVEL PIPERAZINE ANALOGS AS BROAD-SPECTRUM INFLUENZA ANTIVIRALS | BRISTOL-MYERS SQUIBB COMPANY | 2012-09-20 | — | — | US | disclosed |
| WO-2012033736-A1 | NOVEL PIPERAZINE ANALOGS AS BROAD-SPECTRUM INFLUENZA ANTIVIRALS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-03-15 | — | — | WO | disclosed |
| WO-2012033736-A1 | NOVEL PIPERAZINE ANALOGS AS BROAD-SPECTRUM INFLUENZA ANTIVIRALS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120238539-A1 | NOVEL PIPERAZINE ANALOGS AS BROAD-SPECTRUM INFLUENZA ANTIVIRALS | ZC3HAV1, ZC3HAV1L, HCRTR1 | NOTUM 3982/4885CYP19A1 3029/4885KCNJ1 568/4885 |
| US-11230534-B2 | KDM1A inhibitors for the treatment of disease | KDM1B, KDM1A, KDM2A | NOTUM 4775/4885CYP19A1 2710/4885KCNJ1 3045/4885 |
| US-20220073477-A1 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | KDM1B, KDM1A, KDM2A | NOTUM 4775/4885CYP19A1 2710/4885KCNJ1 3045/4885 |
| US-20230000835-A1 | LYSINE-SPECIFIC HISTONE DEMETHYLASE INHIBITORS FOR THE TREATMENT OF MYELOPROLIFERATIVE NEOPLASMS | KDM1B, KDM1A, KDM3A | NOTUM 2263/4885CYP19A1 2140/4885KCNJ1 3912/4885 |
| US-11773068-B2 | KDM1A inhibitors for the treatment of disease | KDM1B, KDM1A, KDM2A | NOTUM 4775/4885CYP19A1 2710/4885KCNJ1 3045/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.